SAT-3247 Shows Positive Six-Month Data in DMD Adults, Reducing Muscle Fat and Improving Effort
MSLE sits 54% above its 52-week low of $5.44.
Summary
Satellos Bioscience reported positive six-month interim data for its lead drug candidate, SAT-3247, in adult Duchenne Muscular Dystrophy (DMD) patients. The TRAILHEAD study showed reduced muscle fat fraction (mean 3.7% improvement), increased upper limb effort (mean 34% improvement), stable strength, lower CK levels, and a favorable safety profile. This follows the FDA Fast Track designation for SAT-3247 announced on June 29th and the company's prior commitment to present this data. These results are highly significant for a clinical-stage biotech, indicating potential efficacy and safety in a challenging patient population. The company plans to complete enrollment in its BASECAMP pediatric DMD study and initiate US clinical trial sites for TRAILHEAD in Q3 this year.
At the time of this announcement, MSLE was trading at $8.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171M. The 52-week trading range was $5.44 to $144.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.